Sharda Cropchem Q1 Results FY27 : Uniresearch Prediction, Analyst Views and Watchpoints

June 26, 2026
Posted by: Kunal Singla
Category: News

Sharda Cropchem Q1 Results FY27: Revenue Rs 1,236 Cr (+25.5% YoY) | PAT Rs 214 Cr (+50.0% YoY), Uniresearch estimate.

Sharda Cropchem Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue at Rs 1,236 Cr (+25.5% YoY) and PAT at Rs 214 Cr (+50.0% YoY), based on the Uniresearch estimate. Q4 FY26 consolidated Revenue stood at Rs 2,065 Cr and PAT at Rs 319 Cr per consolidated quarterly financial data. Prepared by Kunal Singla, Associate Director.

Click Here – Get Free Investment Predictions

Table of Contents

Sharda Cropchem Q1 Results FY27: Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change
Revenue (Rs Cr)	985	1,236	+25.5%
PAT (Rs Cr)	143	214	+50.0%

Source: Q1 FY26 actuals from consolidated quarterly financial data. Sharda Cropchem Q1 Results FY27 prediction applies Uniresearch trailing growth rates (Revenue +25.5%, PAT +50.0%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Track Sharda Cropchem Live on Univest

Q4 FY26 Performance: Base for the Prediction

The Sharda Cropchem Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 2,065 Cr and PAT of Rs 319 Cr per consolidated quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 Results FY27 Uniresearch projection.

The sequential comparison also provides useful context for interpreting the Q1 Results FY27 numbers. Q4 FY26 Revenue of Rs 2,065 Cr reflects year-end procurement and execution cycles that may not repeat equally in the Q1 FY27. For this reason, the more meaningful benchmark for investors is the year-on-year comparison: Q1 FY27 against Q1 FY26 actual Revenue of Rs 985 Cr, where the Uniresearch estimate targets +25.5% growth. Both the YoY and sequential reads should be monitored when the actual Q1 Results FY27 numbers are declared.

Uniresearch Estimate Behind the Sharda Cropchem Q1 Results FY27 Projection

The Sharda Cropchem Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates FY27 Revenue growth of +25.5% and PAT growth of +50.0% year-on-year. Uniresearch applies these consensus growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 1,236 Cr Revenue and Rs 214 Cr PAT.

The Q1 FY27 estimation methodology for Sharda Cropchem is worth clarifying for investors. Uniresearch applies full-year FY27 Uniresearch estimate growth rates (+25.5% Revenue, +50.0% PAT) to Q1 FY26 verified actuals to derive the Q1 FY27 projection of Rs 1,236 Cr Revenue and PAT Rs 214 Cr. This approach assumes the quarterly trajectory broadly mirrors the full-year consensus direction. Intra-year seasonality and one-time events can cause actual quarterly performance to diverge from this projection. Treat this Q1 FY27 Uniresearch estimate for Sharda Cropchem as a directional benchmark, not a point forecast.

Get Expert Stock Picks on Univest

Key Watchpoints for the Sharda Cropchem Q1 Results FY27

Revenue vs Consensus Target

Whether Q1 Results FY27 Revenue delivers in line with the Rs 1,236 Cr Uniresearch estimate (+25.5% YoY). Q4 FY26 Revenue was Rs 2,065 Cr.

PAT Margin Sustainability

PAT of Rs 214 Cr (+50.0% YoY) is the Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 319 Cr. Margin stability signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond the Q1 FY27 headline numbers, Sharda Cropchem’s management commentary at the results announcement will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook from management following an in-line or beat result could support re-rating, while cautious guidance despite solid numbers may limit near-term upside. Track post-result commentary on the Univest Screener for a complete picture.

Risks to the Sharda Cropchem Q1 Results FY27 Prediction

Below-Consensus Revenue Growth

If actual Q1 Results FY27 Revenue underperforms the +25.5% growth target, the Rs 1,236 Cr prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges or higher costs could push PAT below Rs 214 Cr.

External and Macro Environment

The Sharda Cropchem Q1 Results FY27 performance is also exposed to macro-level risks beyond Sharda Cropchem’s direct control. Global commodity price movements, rupee-dollar exchange rate swings, domestic interest rate changes, and shifts in FII and DII sentiment toward the sector can affect input costs, realisations, and investor appetite simultaneously. A deteriorating macro environment in the Q1 FY27 could create downside risk to the Uniresearch Q1 FY27 projection even if company-specific execution remains on track.

Sharda Cropchem Q1 Results FY27: Conclusion

The Sharda Cropchem Q1 FY27 Uniresearch projection of Revenue Rs 1,236 Cr and PAT Rs 214 Cr is derived from Uniresearch trailing analysis. Track Sharda Cropchem live on the Univest Screener for real-time updates.

Use the Univest Screener to Track Sharda Cropchem Live

Download the Univest iOS App or Univest Android App for live Sharda Cropchem Q1 FY27 result alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 projections are derived from Uniresearch estimate growth rates applied to Q1 FY26 actuals. These are consensus-based estimates, not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

Frequently Asked Questions on Sharda Cropchem Q1 Results FY27

What is the Uniresearch prediction for Sharda Cropchem Q1 Results FY27?

Ans. Uniresearch projects Sharda Cropchem Q1 Results FY27 Revenue at Rs 1,236 Cr (+25.5% YoY) and PAT at Rs 214 Cr (+50.0% YoY), based on the Uniresearch estimate. Q1 FY26 actuals were Revenue Rs 985 Cr and PAT Rs 143 Cr.

What Uniresearch estimate is used for the Sharda Cropchem Q1 Results FY27 prediction?

Ans. The Sharda Cropchem Q1 Results FY27 prediction uses Uniresearch trailing analysis, projecting FY27 Revenue growth of +25.5% and PAT growth of +50.0% YoY. Average 12-month price target: Rs 2,313.

What were Q4 FY26 actuals behind the Sharda Cropchem Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 2,065 Cr and PAT was Rs 319 Cr per consolidated quarterly financial data.

How reliable is the Sharda Cropchem Q1 Results FY27 Uniresearch prediction?

Ans. The estimate is consensus-based, not a guaranteed outcome. Actual results may differ due to macro conditions and sector dynamics.

What base data is used for the Sharda Cropchem Q1 Results FY27 Uniresearch projection?

Ans. The Uniresearch projection for Q1 Results FY27 uses Q1 FY26 consolidated actuals (Revenue Rs 985 Cr, PAT Rs 143 Cr) as the base, sourced from Screener.in quarterly financial data. Trailing YoY growth rates (Revenue +25.5%, PAT +50.0%) are applied to these actuals to derive the Q1 Results FY27 estimate. Actuals and projections can be tracked on the Univest Screener.

What are the key risks to the Sharda Cropchem Q1 Results FY27 estimate?

Ans. Key risks: below-consensus revenue growth, margin compression, one-time provisions reducing PAT below Rs 214 Cr.

When will Sharda Cropchem declare the actual Sharda Cropchem Q1 Results FY27 data?

Ans. Sharda Cropchem will declare Q1 FY27 results after the quarter ends. Track live updates on the Univest Screener.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.